Search

Rommelag BFS key to rapid vaccine production

Blow-Fill-Seal production lines using Rommelag equipment will be able to fill-finish more than 500 million doses per year of vaccines.


Fareva to use Blow-Fill-Seal and ApiJect innovative prefilled injector technology to bring high-speed, high-volume fill-finish capacity domestically to France of vaccines and large molecule injectable drugs starting in H2 2022


Fareva and ApiJect Systems, Corp. today announced a 10-year licensing agreement to install three Blow-Fill-Seal production lines that when operational will be able to fill-finish more than 500 million doses per year of vaccines and other large molecule injectable drugs using ApiJect's innovative prefilled injector technology. Fareva intends to invest more than €50M (US$ 56.5M) for these three manufacturing lines, with support from the Government of France, through the "France Relance" industry initiative and the Investments for the Future Program (PIA).

The three manufacturing lines and ApiJect's technology utilize the Blow-Fill-Seal (BFS) aseptic packaging process. BFS has demonstrated its ability to package certain vaccines and large molecule formulations, and ApiJect is helping to expand BFS's capabilities to additional drug products, including temperature sensitive pharmaceuticals. When cleared by regulators, ApiJect will provide the necessary needle hub and other attachable components to convert finished BFS single-dose containers from these lines into easy-to-assemble, ready-to-use prefilled injectors.

Fareva and ApiJect Systems, Corp. today announced a 10-year licensing agreement to install three Blow-Fill-Seal production lines that when operational will be able to fill-finish more than 500 million doses per year of vaccines and other large molecule injectable drugs using ApiJect's innovative prefilled injector technology. Fareva intends to invest more than €50M (US$ 56.5M) for these three manufacturing lines, with support from the Government of France, through the "France Relance" industry initiative and the Investments for the Future Program (PIA).

The three manufacturing lines and ApiJect's technology utilize the Blow-Fill-Seal (BFS) aseptic packaging process. BFS has demonstrated its ability to package certain vaccines and large molecule formulations, and ApiJect is helping to expand BFS's capabilities to additional drug products, including temperature sensitive pharmaceuticals. When cleared by regulators, ApiJect will provide the necessary needle hub and other attachable components to convert finished BFS single-dose containers from these lines into easy-to-assemble, ready-to-use prefilled injectors.

The BFS machines will be purchased from Rommelag in Germany.

NEWS PROVIDED BY

ApiJect Systems Corp.

Dec 09, 2021, 11:31 ETF

Full article available here